198
Views
20
CrossRef citations to date
0
Altmetric
Review

Pregnancy and thrombophilia

, &
Pages 753-765 | Published online: 10 Jan 2014

References

  • Bremme KA. Haemostatic changes in pregnancy. Best Pract. Res. Clin. Haematol.16(2), 153–168 (2003).
  • Ginsberg JS, Brill-Edwards P, Burrows RF et al. Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb. Haemost.67(5), 519–520 (1992).
  • Beller FK, Ebert C. The coagulation and fibrinolytic enzyme system in pregnancy and in the puerperium. Eur. J. Obstet. Gynecol. Reprod. Biol.13(3), 177–197 (1982).
  • Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW. Haemostasis in normal pregnancy. Thromb. Haemost.52(2), 176–182 (1984).
  • Cerneca F, Ricci G, Simeone R, Malisano M, Alberico S, Guaschino S. Coagulation and fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. Eur. J. Obstet. Gynecol. Reprod. Biol.73(1), 31–36 (1997).
  • Condie RG. A serial study of coagulation factors XII, XI and X in plasma in normal pregnancy and in pregnancy complicated by pre-eclampsia. Br. J. Obstet. Gynaecol.83(8), 636–639 (1976).
  • Kjellberg U, Andersson NE, Rosen S, Tengborn L, Hellgren M. APC resistance and other haemostatic variables during pregnancy and puerperium. Thromb. Haemost.81(4), 527–531 (1999).
  • Lefkowitz JB, Clarke SH, Barbour LA. Comparison of protein S functional and antigenic assays in normal pregnancy. Am. J. Obstet. Gynecol.175(3 Pt 1), 657–660 (1996).
  • Comp PC, Thurnau GR, Welsh J, Esmon CT. Functional and immunologic protein S levels are decreased during pregnancy. Blood68(4), 881–885 (1986).
  • Faught W, Garner P, Jones G, Ivey B. Changes in protein C and protein S levels in normal pregnancy. Am. J. Obstet. Gynecol.172(1 Pt 1), 147–150 (1995).
  • Cumming AM, Tait RC, Fildes S, Yoong A, Keeney S, Hay CR. Development of resistance to activated protein C during pregnancy. Br. J. Haematol.90(3), 725–727 (1995).
  • Mathonnet F, de Mazancourt P, Bastenaire B et al. Activated protein C sensitivity ratio in pregnant women at delivery. Br. J. Haematol.92(1), 244–246 (1996).
  • Ishii A, Yamada S, Yamada R, Hamada H. t-PA activity in peripheral blood obtained from pregnant women. J. Perinat. Med.22(2), 113–117 (1994).
  • Nilsson IM, Felding P, Lecander I, Lenner C, Astedt B. Different types of plasminogen activator inhibitors in plasma and platelets in pregnant women. Br. J. Haematol.62(2), 215–220 (1986).
  • Lecander I, Astedt B. Specific plasminogen activator inhibitor of placental type PAI 2 occurring in amniotic fluid and cord blood. J. Lab. Clin. Med.110(5), 602–605 (1987).
  • Astedt B, Hagerstrand I, Lecander I. Cellular localisation in placenta of placental type plasminogen activator inhibitor. Thromb. Haemost.56(1), 63–65 (1986).
  • de Boer K, ten Cate JW, Sturk A, Borm JJ, Treffers PE. Enhanced thrombin generation in normal and hypertensive pregnancy. Am. J. Obstet. Gynecol.160(1), 95–100 (1989).
  • Chabloz P, Reber G, Boehlen F, Hohlfeld P, de Moerloose P. TAFI antigen and d-dimer levels during normal pregnancy and at delivery. Br. J. Haematol.115(1), 150–152 (2001).
  • Ghirardini G, Battioni M, Bertellini C, Colombini R, Colla R, Rossi G. d-dimer after delivery in uncomplicated pregnancies. Clin. Exp. Obstet. Gynecol.26(3–4), 211–212 (1999).
  • Sheppard BL, Bonnar J. Uteroplacental hemostasis in intrauterine fetal growth retardation. Semin. Thromb. Hemost.25(5), 443–446 (1999).
  • Knight M, Redman CW, Linton EA, Sargent IL. Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies. Br. J. Obstet. Gynaecol.105(6), 632–640 (1998).
  • Lindqvist P, Dahlback B, Marsal K. Thrombotic risk during pregnancy: a population study. Obstet. Gynecol.94(4), 595–599 (1999).
  • Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet353(9160), 1258–1265 (1999).
  • Eldor A. Thrombophilia, thrombosis and pregnancy. Thromb. Haemost.86(1), 104–111 (2001).
  • James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am. J. Obstet. Gynecol.194(5), 1311–1315 (2006).
  • Macklon NS, Greer IA, Bowman AW. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br. J. Obstet. Gynaecol.104(2), 191–197 (1997).
  • Martinelli I, De Stefano V, Taioli E, Paciaroni K, Rossi E, Mannucci PM. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb. Haemost.87(5), 791–795 (2002).
  • Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet. Gynecol. Surv.54(4), 265–271 (1999).
  • Macklon NS, Greer IA. Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience. Scott. Med. J.41(3), 83–86 (1996).
  • Pabinger I, Grafenhofer H, Kyrle PA et al. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood100(3), 1060–1062 (2002).
  • Conard J, Horellou MH, Van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb. Haemost.63(2), 319–320 (1990).
  • De Stefano V, Leone G, Mastrangelo S et al. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb. Haemost.72(3), 352–358 (1994).
  • De Stefano V, Leone G, Mastrangelo S et al. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb. Haemost.71(6), 799–800 (1994).
  • Dahlback B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood85(3), 607–614 (1995).
  • Dahlback B. Thrombophilia: the discovery of activated protein C resistance. Adv. Genet.33, 135–175 (1995).
  • Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood85(6), 1504–1508 (1995).
  • Bokarewa MI, Bremme K, Blomback M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br. J. Haematol.92(2), 473–478 (1996).
  • Hallak M, Senderowicz J, Cassel A et al. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am. J. Obstet. Gynecol.176(4), 889–893 (1997).
  • Gerhardt A, Scharf RE, Beckmann MW et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N. Engl. J. Med.342(6), 374–380 (2000).
  • Dizon-Townson D, Miller C, Sibai B et al. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet. Gynecol.106(3), 517–524 (2005).
  • Gerhardt A, Scharf RE, Zotz RB. Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium. Thromb. Haemost.90(1), 77–85 (2003).
  • McColl MD, Ellison J, Reid F, Tait RC, Walker ID, Greer IA. Prothrombin 20210 G-->A, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. Br. J. Obstet. Gynaecol.107(4), 565–569 (2000).
  • Greer IA. The challenge of thrombophilia in maternal–fetal medicine. N. Engl. J. Med.342(6), 424–425 (2000).
  • Petri M. Epidemiology of the antiphospholipid antibody syndrome. J. Autoimmun.15(2), 145–151 (2000).
  • Pattison NS, Chamley LW, McKay EJ, Liggins GC, Butler WS. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br. J. Obstet. Gynaecol.100(10), 909–913 (1993).
  • MacLean MA, Cumming GP, McCall F, Walker ID, Walker JJ. The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages. Br. J. Obstet. Gynaecol.101(2), 103–106 (1994).
  • Asherson RA, Khamashta MA, Ordi-Ros J et al. The “primary” antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore)68(6), 366–374 (1989).
  • Ginsburg KS, Liang MH, Newcomer L et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann. Intern. Med.117(12), 997–1002 (1992).
  • Ahmed E, Stegmayr B, Trifunovic J, Weinehall L, Hallmans G, Lefvert AK. Anticardiolipin antibodies are not an independent risk factor for stroke: an incident case-referent study nested within the MONICA and Vasterbotten cohort project. Stroke31(6), 1289–1293 (2000).
  • Vila P, Hernandez MC, Lopez-Fernandez MF, Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb. Haemost.72(2), 209–213 (1994).
  • Hammerslough CR. Estimating the probability of spontaneous abortion in the presence of induced abortion and vice versa.Public Health Rep.107(3), 269–277 (1992).
  • Rai R, Regan L, Hadley E, Dave M, Cohen H. Second-trimester pregnancy loss is associated with activated C resistance. Br. J. Haematol.92(2), 489–490 (1996).
  • Pauer HU, Neesen J, Hinney B. Factor V Leiden and its relevance in patients with recurrent abortions. Am. J. Obstet. Gynecol.178(3), 629 (1998).
  • Kovalevsky G, Gracia CR, Berlin JA, Sammel MD, Barnhart KT. Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis. Arch. Intern. Med.164(5), 558–563 (2004).
  • Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet361(9361), 901–908 (2003).
  • Lockshin MD, Druzin ML, Goei S et al. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N. Engl. J. Med.313(3), 152–156 (1985).
  • Lockshin MD. Lupus pregnancy. Clin. Rheum. Dis.11(3), 611–632 (1985).
  • Branch DW, Silver R, Pierangeli S, van Leeuwen I, Harris EN. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Obstet. Gynecol.89(4), 549–555 (1997).
  • Bocciolone L, Meroni P, Parazzini F et al. Antiphospholipid antibodies and risk of intrauterine late fetal death. Acta Obstet. Gynecol. Scand.73(5), 389–392 (1994).
  • Meroni PL, di Simone N, Testoni C, D’Asta M, Acaia B, Caruso A. Antiphospholipid antibodies as cause of pregnancy loss. Lupus13(9), 649–652 (2004).
  • Rand JH, Wu XX, Guller S et al. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am. J. Obstet. Gynecol.171(6), 1566–1572 (1994).
  • Chamley LW, Pattison NS, Liddell H. β2 glycoprotein I-dependent anticardiolipin antibodies in recurrent miscarriage. Hum. Reprod.13(7), 2033–2034 (1998).
  • Chamley LW, Duncalf AM, Mitchell MD, Johnson PM. Action of anticardiolipin and antibodies to β2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death. Lancet352(9133), 1037–1038 (1998).
  • Sthoeger ZM, Mozes E, Tartakovsky B. Anti-cardiolipin antibodies induce pregnancy failure by impairing embryonic implantation. Proc. Natl Acad. Sci. USA90(14), 6464–6467 (1993).
  • Lyden TW, Vogt E, Ng AK, Johnson PM, Rote NS. Monoclonal antiphospholipid antibody reactivity against human placental trophoblast. J. Reprod. Immunol.22(1), 1–14 (1992).
  • Bonet B, Hauge-Gillenwater H, Zhu XD, Knopp RH. LDL oxidation and human placental trophoblast and macrophage cytotoxicity. Proc. Soc. Exp. Biol. Med.217(2), 203–211 (1998).
  • Horkko S, Miller E, Dudl E et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J. Clin. Invest.98(3), 815–825 (1996).
  • Holers VM, Girardi G, Mo L et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J. Exp. Med.195(2), 211–220 (2002).
  • Saftlas AF, Olson DR, Franks AL, Atrash HK, Pokras R. Epidemiology of preeclampsia and eclampsia in the United States, 1979–1986. Am. J. Obstet. Gynecol.163(2), 460–465 (1990).
  • Dekker GA, de Vries JI, Doelitzsch PM et al. Underlying disorders associated with severe early-onset preeclampsia. Am. J. Obstet. Gynecol.173(4), 1042–1048 (1995).
  • Kupferminc MJ, Eldor A, Steinman N et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N. Engl. J. Med.340(1), 9–13 (1999).
  • Livingston JC, Barton JR, Park V, Haddad B, Phillips O, Sibai BM. Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia. Am. J. Obstet. Gynecol.185(1), 153–157 (2001).
  • De Maat MP, Jansen MW, Hille ET et al. Preeclampsia and its interaction with common variants in thrombophilia genes. J. Thromb. Haemost.2(9), 1588–1593 (2004).
  • D’Anna R, Baviera G, Corrado F, Ientile R, Granese D, Stella NC. Plasma homocysteine in early and late pregnancies complicated with preeclampsia and isolated intrauterine growth restriction. Acta Obstet. Gynecol. Scand.83(2), 155–158 (2004).
  • von Tempelhoff GF, Heilmann L, Spanuth E, Kunzmann E, Hommel G. Incidence of the factor V Leiden-mutation, coagulation inhibitor deficiency, and elevated antiphospholipid-antibodies in patients with preeclampsia or HELLP-syndrome. Hemolysis, elevated liver-enzymes, low platelets. Thromb. Res.100(4), 363–365 (2000).
  • de Vries JI, Dekker GA, Huijgens PC, Jakobs C, Blomberg BM, van Geijn HP. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br. J. Obstet. Gynaecol.104(11), 1248–1254 (1997).
  • Kupferminc MJ, Many A, Bar-Am A, Lessing JB, Ascher-Landsberg J. Mid-trimester severe intrauterine growth restriction is associated with a high prevalence of thrombophilia. Br. J. Obstet. Gynaecol.109(12), 1373–1376 (2002).
  • Infante-Rivard C, Rivard GE, Yotov WV et al. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N. Engl. J. Med.347(1), 19–25 (2002).
  • van der Molen EF, Verbruggen B, Novakova I, Eskes TK, Monnens LA, Blom HJ. Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy. Br. J. Obstet. Gynaecol.107(6), 785–791 (2000).
  • Lagrange F, Vergnes C, Brun JL et al. Absence of placental transfer of pentasaccharide (fondaparinux, arixtra) in the dually perfused human cotyledon in vitro.Thromb. Haemost.87(5), 831–835 (2002).
  • Harenberg J. Treatment of a woman with lupus and thromboembolism and cutaneous intolerance to heparins using fondaparinux during pregnancy. Thromb. Res.119(3), 385–388 (2007).
  • Flessa HC, Kapstrom AB, Glueck HI, Will JJ. Placental transport of heparin. Am. J. Obstet. Gynecol.93(4), 570–573 (1965).
  • Forestier F, Daffos F, Rainaut M, Toulemonde F. Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy. Thromb. Haemost.57(2), 234 (1987).
  • Ginsberg JS, Hirsh J. Anticoagulants during pregnancy. Annu. Rev. Med.40, 79–86 (1989).
  • Ginsberg JS, Hirsh J, Turner DC, Levine MN, Burrows R. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb. Haemost.61(2), 197–203 (1989).
  • Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am. J. Med.68(1), 122–140 (1980).
  • Pauli RM, Hall JG, Wilson KM. Risks of anticoagulation during pregnancy. Am. Heart J.100(5), 761–762 (1980).
  • Weitz JI. Low-molecular-weight heparins. N. Engl. J. Med.337(10), 688–698 (1997).
  • Blomback M, Bremme K, Hellgren M, Lindberg H. A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. Blood Coagul. Fibrinolysis9(4), 343–350 (1998).
  • Rodie VA, Thomson AJ, Stewart FM, Quinn AJ, Walker ID, Greer IA. Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series. Br. J. Obstet. Gynaecol.109(9), 1020–1024 (2002).
  • Warkentin TE. Think of HIT when thrombosis follows heparin. Chest130(3), 631–632 (2006).
  • Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J. Lab. Clin. Med.146(6), 341–346 (2005).
  • Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb. Haemost.70(4), 554–561 (1993).
  • Douketis JD, Ginsberg JS, Burrows RF, Duku EK, Webber CE, Brill-Edwards P. The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb. Haemost.75(2), 254–257 (1996).
  • Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb. Haemost.71(1), 7–11 (1994).
  • McKenna R, Cole ER, Vasan U. Is warfarin sodium contraindicated in the lactating mother? J. Pediatr.103(2), 325–327 (1983).
  • Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest126(3 Suppl.), 627S–644S (2004).
  • Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest119(1 Suppl.), 122S–131S (2001).
  • Krivak TC, Zorn KK. Venous thromboembolism in obstetrics and gynecology. Obstet. Gynecol.109(3), 761–777 (2007).
  • Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation93(12), 2212–2245 (1996).
  • Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N. Engl. J. Med.336(21), 1506–1511 (1997).
  • Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am. J. Obstet. Gynecol.168(4), 1265–1270 (1993).
  • Demers C, Ginsberg JS. Deep venous thrombosis and pulmonary embolism in pregnancy. Clin. Chest Med.13(4), 645–656 (1992).
  • Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am. J. Obstet. Gynecol.174(5), 1584–1589 (1996).
  • Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br. Med. J.314(7076), 253–257 (1997).
  • Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb. Haemost.83(5), 693–697 (2000).
  • Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J. Thromb. Haemost.1(3), 433–438 (2003).
  • Gris JC, Mercier E, Quere I et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood103(10), 3695–3699 (2004).
  • Brenner B, Hoffman R, Carp H, Dulitsky M, Younis J. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J. Thromb. Haemost.3(2), 227–229 (2005).
  • Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost.4(2), 295–306 (2006).
  • Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb. Haemost.74(4), 1185–1190 (1995).
  • Wisloff F, Jacobsen EM, Liestol S. Laboratory diagnosis of the antiphospholipid syndrome. Thromb. Res.108(5–6), 263–271 (2002).
  • Tincani A, Allegri F, Sanmarco M et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations – a cooperative project of the European Antiphospholipid Forum. Thromb. Haemost.86(2), 575–583 (2001).
  • Reber G, Tincani A, Sanmarco M, de Moerloose P, Boffa MC. Proposals for the measurement of anti-β2-glycoprotein I antibodies. Standardization group of the European Forum on Antiphospholipid Antibodies. J. Thromb. Haemost.2(10), 1860–1862 (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.